Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.530 -0.100 (-3.80%)
Delayed Quote Updated: 11:23 AM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 137,711
Open 2.570
Bid (Size) 2.530 (600)
Ask (Size) 2.540 (1,400)
Prev. Close 2.630
Today's Range 2.510 - 2.610
52wk Range 1.620 - 5.055
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Final Step Completed for FDA Process Validation; Two-Year Stability for Preservative-Free Ketamine Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

52-Week Range 50.0% below 52-week high
2.530
1.6252W Low 5.0552W High
1 Week 10.1% below 1-week high
2.481W Low 2.811W High

NRX Pharmaceuticals, Inc. - Common Stock (NRXP) traded between $1.62 and $5.05 over the past 52 weeks and last traded at $2.53, 50.0% below its 52-week high. Over the past week it ranged between $2.48 and $2.81.

Past 12 Months
-6.6%
-23.1%
-43.5%
-14.8%
-3.4%
-21.2%
1W -$0.18
1M -$0.76
3M -$1.95
6M -$0.44
YTD -$0.09
1Y -$0.68

NRXP was -21.2% over the past year, -14.8% over six months, -3.4% year to date, -6.6% in the last week.

12 Months vs Market
NRXP
-21.2%
DIA
+12.3%
SPY
+13.9%
QQQ
+16.0%
IWM
+11.7%

Over the past 12 months NRXP returned -21.2% versus DIA (Dow) +12.3%, SPY (S&P 500) +13.9%, QQQ (Nasdaq 100) +16.0% and IWM (Russell 2000) +11.7%.

Volume & Liquidity 0.16× 3-mo avg
Today 137,711 3-mo avg 873.9K
1W
1.1M
1M
699.9K
3M
873.9K
6M
1.0M
YTD
1.0M
1Y
934.3K

NRXP most recently traded 137,711 shares against a 3-month average daily volume of 873.9K.

More News

Read More
News headline image
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
$11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression Greatly Expands Application Potential for NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Intellectual Property
News headline image
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
First Interventional Psychiatry Use of FDA-Cleared Zeta TMS AI Driven Robotic System in Treatment of Suicidal Bipolar Depression by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Artificial Intelligence
News headline image
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
News headline image
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
Via Benzinga
Topics Earnings
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles ↗
Via MarketBeat
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Government
News headline image
New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.
From New to The Street
Via ACCESS Newswire
News headline image
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
From New to The Street
Via ACCESS Newswire
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
These stocks are moving in today's pre-market session ↗
Via Chartmill

Frequently Asked Questions

Is NRX Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, NRX Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does NRX Pharmaceuticals, Inc. - Common Stock trade on?
NRX Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock is NRXP on the Nasdaq Stock Market
What is the current price of NRX Pharmaceuticals, Inc. - Common Stock?
The current price of NRX Pharmaceuticals, Inc. - Common Stock is 2.530
When was NRX Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of NRX Pharmaceuticals, Inc. - Common Stock was at 10/22/26 11:23 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.